GSK updates total voting rights and share capital

GSK plc reported its total voting rights and share capital as of 30 June 2026.

Rhea-AI Filing Summary

GSK plc reported its total voting rights and share capital as of 30 June 2026. The company had 4,316,276,428 issued ordinary shares of 31¼ pence each, including 270,881,064 shares held in treasury.

This leaves 4,045,395,364 voting rights, which shareholders can use as the reference figure when deciding whether they must disclose holdings or changes under the UK Financial Conduct Authority’s transparency rules.

Key Figures

Issued share capital: 4,316,276,428 shares Treasury shares: 270,881,064 shares Total voting rights: 4,045,395,364 +1 more

4 metrics

Issued share capital 4,316,276,428 shares Ordinary shares of 31¼ pence each as of 30 June 2026

Treasury shares 270,881,064 shares Ordinary shares held in treasury as of 30 June 2026

Total voting rights 4,045,395,364 Voting rights in GSK plc as of 30 June 2026

Nominal value per share 31¼ pence Nominal value of each ordinary share

Key Terms

Total Voting Rights, treasury, Disclosure Guidance and Transparency Rule 5.6.1R, voting rights

4 terms

Total Voting Rights financial

"Total Voting Rights In conformity with the Financial Conduct Authority's Disclosure Guidance"

The total voting rights number is the count of shares that carry the right to vote at a company’s shareholder meetings, reflecting how much voting power exists in the market. Investors use it to understand control and influence—like knowing how many votes are in play when measuring ownership stakes, calculating a shareholder’s voting percentage, or assessing how easy it would be for a holder to sway decisions.

treasury financial

"of which 270,881,064 Ordinary Shares were held in Treasury."

The treasury is the department or area within a government or organization responsible for managing its money, finances, and financial strategies. It handles tasks like collecting revenue, paying bills, and planning for future financial needs, much like a household manages its budget. For investors, understanding the treasury is important because it influences interest rates, government spending, and overall economic stability.

Disclosure Guidance and Transparency Rule 5.6.1R regulatory

"In conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R"

voting rights financial

"Therefore, the total number of voting rights in the Company is 4,045,395,364."

Voting rights are the ability of shareholders to have a say in important company decisions, like choosing leaders or approving big changes. They matter because they give owners a voice in how the company is run, similar to how voters influence elections, ensuring the company acts in shareholders’ interests.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What total voting rights did GSK (GSK) report for 30 June 2026?

GSK reported a total of 4,045,395,364 voting rights as of 30 June 2026. Shareholders can use this figure as the denominator when assessing whether they must notify their shareholdings under UK transparency rules.

How many GSK (GSK) shares were in issue at 30 June 2026?

GSK stated its issued share capital consisted of 4,316,276,428 ordinary shares of 31¼ pence each at 30 June 2026. This total includes shares held in treasury, which do not carry voting rights while held there.

How many GSK (GSK) shares were held in treasury?

GSK reported holding 270,881,064 ordinary shares in treasury as of 30 June 2026. Treasury shares are issued but do not carry voting rights, reducing the number of voting shares compared with total shares in issue.

Why does GSK (GSK) publish its total voting rights figure?

GSK publishes total voting rights to help investors comply with FCA Disclosure Guidance and Transparency Rule 5.6.1R. Shareholders use the stated voting rights number to determine when they must notify interests or changes in interests in the company.

Who signed GSK’s (GSK) July 2026 total voting rights notification?

The notification was signed by Victoria Whyte, acting as an authorised signatory on behalf of GSK plc. The company identified her as the Company Secretary in the accompanying information within the same report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/01/2026 - 10:02 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

Issued: 1 July 2026, London UK

Total Voting Rights

In conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R, GSK plc (the 'Company') hereby notifies the market of the following:

The Company's issued share capital as at 30 June 2026 consisted of 4,316,276,428 shares of 31 ¼ pence each ('Ordinary Shares'), of which 270,881,064 Ordinary Shares were held in Treasury.

Therefore, the total number of voting rights in the Company is 4,045,395,364. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Notifications may be sent to company.secretary@gsk.com.

V A Whyte

Company Secretary

1 July 2026

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: July 01, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc